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Abstract
Background—Uremic symptoms are major contributors to the poor quality of life among 
patients on dialysis, but whether their prevalence or intensity has changed over time is unknown.
Methods—We examined responses to validated questionnaires in two incident dialysis cohort 
studies, the Choices for Health Outcomes in Caring for ESRD (CHOICE) study (N=926, 1995–
1998) and the Longitudinal United States/Canada Incident Dialysis (LUCID) study (N=428, 
2011–2017). We determined the prevalence and severity of uremic symptoms—anorexia, nausea/
vomiting, pruritus, sleepiness, difficulty concentrating, fatigue, and pain—in both cohorts.
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Results—In CHOICE and LUCID, respectively, mean age of the participants was 58 and 60 
years, 53% and 60% were male, and 28% and 32% were black. In both cohorts, 54% of the 
participants had diabetes. Median time from dialysis initiation to the symptoms questionnaires was 
45 days for CHOICE and 77 days for LUCID. Uremic symptom prevalence in CHOICE did not 
change from baseline to 1-year follow-up and was similar across CHOICE and LUCID. Baseline 
symptom prevalence in CHOICE and LUCID was as follows: anorexia (44%, 44%, respectively), 
nausea/vomiting (36%, 43%), pruritus (72%, 63%), sleepiness (86%, 68%), difficulty 
concentrating (55%, 57%), fatigue (89%, 77%), and pain (82%, 79%). In both cohorts, >80% of 
patients had three or more symptoms and >50% had five or more symptoms. The correlation 
between individual symptoms was low (ρ<0.5 for all comparisons). In CHOICE, no clinical or 
laboratory parameter was strongly associated with multiple symptoms.
Conclusions—The burden of uremic symptoms among patients on dialysis is substantial and 
has not changed in the past 15 years. Improving quality of life will require identification of the 
factors that underlie the pathogenesis of uremic symptoms and better ways of removing the toxins 
that are responsible.
Introduction
Over 1 million people will start dialysis for ESKD in the next decade (1). Although dialysis 
prevents death from kidney failure over the short term, many patients continue to suffer from 
uremic symptoms including anorexia, nausea, pruritus, fatigue, excessive daytime 
sleepiness, difficulty concentrating, and pain (2). Uremic symptoms are a major contributor 
to the poor health-related quality of life experienced by patients on dialysis, which is often a 
greater concern than survival for these patients. Indeed, when asked about the possibility of 
improvement in quality of life or survival by switching to intensive hemodialysis, 94% 
would consider it for improving energy, 57% for improving sleep, but only 19% would 
consider it for improving survival at 3 years (3). Further, “the best ways to manage 
symptoms in people receiving or nearing dialysis, including poor energy and nausea” was 
identified as a top research priority in a survey of patients on dialysis and the providers 
caring for them (4,5).
Despite this significant interest from both patients and providers, relatively few studies have 
rigorously examined uremic symptoms in large, longitudinal ESKD cohorts, leaving several 
notable gaps in the existing literature. First, prevalence studies have often focused on 
individual symptoms rather than a broad range of symptoms (6). Second, how uremic 
symptoms change over time after dialysis initiation has not been examined. Third, no studies 
have addressed whether the burden of uremic symptoms experienced by patients on dialysis 
has changed over the past two decades, as might be expected given the numerous changes in 
clinical practice over that time.
To address these gaps, we analyzed data from two prospective cohort studies of patients who 
had recently initiated dialysis, the Choices for Health Outcomes in Caring for ESRD 
(CHOICE) study, which enrolled patients from 1995 to 1998, and the Longitudinal United 
States/Canada Incident Dialysis (LUCID) study, which enrolled patients from 2011 to 2017. 
We compared symptom burden both at study entry and at 1 year after enrollment in 
Rhee et al. Page 2













CHOICE, as well as symptom burden at study entry across both cohorts, which span >20 
years of ESKD care. Longitudinal follow-up in CHOICE further enabled an exploratory 
assessment of the association between symptom burden and longitudinal outcomes. Taken 
together, our study outlines the prevalence and persistence of uremic symptoms among 
patients on dialysis and emphasizes the urgent need for an improved understanding of 
underlying mechanisms (7).
Materials and Methods
We analyzed data from two prospective, incident dialysis cohort studies, the CHOICE study 
(1995–1998) and the LUCID (2011–2017) study.
CHOICE Study
From October 1995 to June 1998,1041 participants (767 on hemodialysis and 274 on 
peritoneal dialysis) were enrolled from 19 states in the United States, a median of 45 days 
after initiation of dialysis (95% within 3.5 months). Eligibility criteria were initiation of 
maintenance dialysis therapy in the preceding 3 months, ability to provide informed consent, 
age >18 years, and ability to speak English or Spanish. Participants were followed for all-
cause mortality through December 31, 2008 and for cardiovascular mortality through 
December 31, 2004. The subset of 926 individuals who filled out the CHOICE Health 
Experience Questionnaire at study entry was included in this analysis. The Johns Hopkins 
Medicine Institutional Review Board (Baltimore, MD) and the Dialysis Clinic, Inc. (DCI) 
Institutional Review Board approved the study, which adhered to the Declaration of 
Helsinki, and participants provided written informed consent.
LUCID Study
From May 2011 to December 2017, 823 participants (808 on hemodialysis, 15 on peritoneal 
dialysis) were enrolled in three centers (New England, Washington, Indiana) a median of 77 
days after initiation of dialysis (95% within 6.0 months); although the original intent was to 
include participants from both the United States and Canada in a single cohort, Canadian 
participants were ultimately enrolled in a separate study. Eligibility criteria were initiation of 
maintenance dialysis, ability to provide informed consent, and age >18 years. The subset of 
428 individuals who filled out a Kidney Disease Quality of Life (KDQOL) survey at study 
entry was included in this analysis. The Massachusetts General Hospital Institutional 
Review Board (Boston, MA) approved the study, which adhered to the Declaration of 
Helsinki, and participants provided written informed consent.
Uremic Symptoms (CHOICE and LUCID)
Symptom prevalence and intensity were assessed by patient responses to self-administered 
questionnaires conducted at study entry. The CHOICE Health Experience Questionnaire (8) 
and KDQOL instrument (9) were used in CHOICE and LUCID, respectively. Both studies 
use similar questions to assess uremic responses, assessing symptoms during the 4 weeks 
preceding the survey. The responses to seven questions (Supplemental Table 1) were used to 
assess anorexia, nausea, pruritus, sleepiness, difficulty concentrating, fatigue, and pain. 
These responses were recorded on a Likert scale and scored in a standardized manner (10). 
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The generated numeric scores have a range of 0–100, with a higher score representing better 
health (lower severity of symptoms). For exploratory analyses in CHOICE, an overall 
uremic symptom score was calculated for each study participant as an average of scores for 
all seven uremic symptoms weighted equally (U-score).
Longitudinal Outcomes (CHOICE)
As an exploratory analysis in CHOICE, we also considered secondary outcomes of all-cause 
mortality, cardiovascular mortality, and first cardiovascular event. Mortality was adjudicated 
using information from clinic report, hospital records, the National Death Index, Centers for 
Medicare and Medicaid Services death notification forms, and Social Security records, as 
previously described (11). We defined first atherosclerotic cardiovascular event (fatal or 
nonfatal) as an event due to myocardial infarction, cardiac revascularization procedure, 
stroke, carotid endarterectomy, extremity gangrene or peripheral revascularization 
procedure, limb amputation, or abdominal aortic aneurysm repair that occurred after 
enrollment in the study (11).
Other Covariates
In CHOICE, we collected data on participants’ age, sex, race, residual kidney function (self-
reported ability to produce more than one cup of urine daily) and body mass index (BMI). 
We adjudicated baseline comorbidities including prevalent cardiovascular disease by 
abstraction of dialysis unit records, hospital discharge summaries, medication lists, 
consultation notes, diagnostic imaging, and cardiac imaging reports and scoring of the Index 
of Coexistent Disease by two trained nurses. In CHOICE, we obtained routine laboratory 
data including serum albumin, creatinine, Kt/Vurea, and phosphate from medical records. In 
LUCID, we collected data on participants’ age, sex, race, residual kidney function (self-
reported ability to produce any urine), BMI, and comorbidities by patient interview and 
abstraction of dialysis unit records.
Statistical Analyses
We described baseline characteristics of participants in CHOICE and LUCID using means 
and proportions, as appropriate. We determined the distribution of the uremic symptoms 
(present versus absent) for each symptom at baseline in both cohorts and compared 
correlation between symptom scores for individual symptoms using Spearman correlation 
coefficients. In CHOICE, we further examined the symptoms at year 1 for participants alive 
at that time point (N=585) and with available data. We examined the cross-sectional 
association between baseline characteristics and individual symptom scores using univariate 
linear regression models. In exploratory analysis, we modeled the U-score as a continuous 
variable to examine associations with longitudinal outcomes. We used Cox proportional 
hazards regression to evaluate the association between U-score at baseline and outcomes 
(any-cause death, cardiac death, first cardiovascular event) during follow-up in the CHOICE 
study. We sequentially adjusted for potential confounders including demographics (age, sex, 
race), comorbidities (Index of Coexistent Disease severity score, cause of ESKD, BMI 
[categorized as <18, 18–25, and >25 kg/m2], residual kidney function (self-reported urine 
volume of more than one cup of urine daily), diabetes, dialysis modality), and predialysis 
laboratory tests (albumin, urea, Kt/Vurea, creatinine, calcium, phosphate, potassium, glucose, 
Rhee et al. Page 4













and cholesterol). Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, 
NC). Statistical significance was defined as P<0.05 using two-tailed tests.
Results
Baseline Characteristics of the Study Sample
Baseline characteristics of study participants are shown in Table 1. The CHOICE and 
LUCID studies included 926 and 428 patients who had recently initiated dialysis who filled 
out symptom surveys, respectively, with similar distributions of age (mean, 58 years versus 
60 years), race (28% black versus 32% black), gender (53% male versus 60% male), 
diabetes status (54% versus 54%), and self-reported residual kidney function (81% versus 
89%). In CHOICE, 75% of participants were on hemodialysis and 25% were on peritoneal 
dialysis. By contrast, almost all participants in LUCID were on hemodialysis (97%). A 
comparison of individuals who did or did not fill out a symptom survey in CHOICE and 
LUCID are shown in Supplemental Tables 2 and 3, respectively. Individuals who did not fill 
out a survey were more likely to be male and be on peritoneal dialysis in CHOICE, and 
more likely to be black in LUCID. Questionnaires were completed at a median of 45 days 
from dialysis initiation (25th to 75th percentiles, 26–73 days) in CHOICE and 77 days from 
dialysis initiation (25th to 75th percentiles, 47–121 days) in LUCID.
Prevalence and Severity of Uremic Symptoms in CHOICE and LUCID
Uremic symptom prevalence and severity in CHOICE was high and did not change 
substantially from baseline to year 1 follow-up (Table 2). Fatigue was the most common 
(89% at baseline and 89% at year 1) and nausea/vomiting was the least common symptom 
(36% at baseline and 40% at year 1). Participants on peritoneal dialysis (Supplemental Table 
2) were more likely than those on hemodialysis to have nausea/vomiting (38% versus 31%, 
P=0.05) and less likely to have anorexia (42% versus 51%, P=0.04). No significant 
differences in symptom prevalence were observed for other symptoms between individuals 
on peritoneal dialysis versus hemodialysis (Supplemental Table 4).
The average symptom prevalence was similar between LUCID and CHOICE despite the 
approximately 15–20 year difference in study enrollments (Table 2). Baseline values in 
CHOICE and LUCID were fatigue (89% and 77%, respectively), anorexia (44% and 44%), 
pruritus (72% and 63%), sleepiness (86% and 68%), nausea/vomiting (36% and 43%), 
difficulty concentrating (55% and 57%), and pain (82% and 79%). In both cohorts, >80% of 
patients had three or more uremic symptoms and >50% had five or more uremic symptoms 
(Figure 1).
Characteristics Associated with Uremic Symptom Burden in CHOICE
The correlation between individual symptoms was low in CHOICE (correlation coefficient 
<0.4 for all comparisons) (Table 3). Similar findings were observed in LUCID 
(Supplemental Table 5). In CHOICE, increased age was associated with lower symptom 
scores for anorexia, sleepiness, nausea/vomiting, and pain; male sex was associated with 
lower symptom scores for anorexia, nausea/vomiting, difficulty concentrating, and pain 
(Table 4). Several clinical characteristics and laboratory parameters had nominally 
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significant associations with symptoms, although several were likely indicative of reverse 
causation (e.g., less anorexia associated with higher BUN, albumin, phosphate, and 
potassium). Considering the multiple comparisons, only a handful of associations were 
significant at a more stringent P<0.001 threshold: increased age with less sleepiness and 
nausea/vomiting, male sex with less nausea/vomiting, and higher BUN with less anorexia. 
No association with any uremic symptom score was observed for diabetes status, BMI <25 
versus ≥25 kg/m2, ESKD cause (diabetes versus other), creatinine, calcium, or glucose.
Association of Uremic Symptoms and Longitudinal Outcomes
In CHOICE, there were 580 deaths (282 cardiac deaths) and 516 cardiovascular events 
during follow-up. Baseline characteristics of individuals alive or dead at 1-year follow-up 
are shown in Supplemental Table 6, demonstrating higher baseline BMI among survivors. In 
exploratory analysis, a higher baseline U-score was associated with any-cause death, cardiac 
death, and first cardiovascular event in age-, sex-, and race-adjusted models (Supplemental 
Table 7). In fully adjusted models, each ten-point-lower U-score (more symptoms) was 
associated with a 5% higher risk of death (hazard ratio [HR], 1.05; 95% CI, 1.01 to 1.10), 
6% higher risk of cardiac death (HR, 1.06; 95% CI, 0.99 to 1.12), and 5% higher risk of first 
cardiovascular event (HR, 1.05; 95% CI, 1.00 to 1.10).
Discussion
Our study has two principal findings. First, uremic symptoms are very common among 
patients with ESKD who have recently initiated dialysis. Very few (<3%) of the patients had 
no symptoms and >80% of the patients experienced three or more uremic symptoms. 
Second, the prevalence of uremic symptoms at or close to initiation of dialysis has been 
remarkably consistent over the past 15 or more years, despite many other changes in patient 
demographics and/or care processes during this time.
In a systematic review of the literature, Murtagh et al. (6) compiled 60 distinct studies of 
ESKD that reported on symptom prevalence. Most of these prior studies examined one or 
two symptoms at a time, and the few studies that looked more broadly across multiple 
symptoms were relatively small (12-16). A recent exception used both focus groups and 
surveys to demonstrate high symptom prevalence in 119 individuals with ESKD (17). In our 
study, we simultaneously assessed the prevalence of key uremic symptoms—fatigue, 
anorexia, pruritus, sleepiness, nausea, difficulty concentrating, and pain—in a total of 1354 
patients, representing the largest sample examined to date. The simultaneous assessment of 
numerous symptoms is valuable, because it most effectively demonstrates the truly grim 
burden of symptoms experienced by patients on dialysis. We found that all symptoms were 
common in CHOICE and LUCID, with individual frequencies of 36%–89%; these values 
are consistent with the mean prevalence values summarized by Murtagh et al (6). Further, 
the majority of patients experienced three or more symptoms, and more than a half of 
patients experienced five or more symptoms. However, the correlation between individual 
symptoms was relatively low, suggesting that underlying mechanisms may differ, further 
reinforcing the value of examining multiple symptoms simultaneously.
Rhee et al. Page 6













Whereas prior studies have examined symptom prevalence, ours is the first to assess whether 
symptom prevalence has improved in the modern era. In the interval between recruitment for 
the CHOICE (1995–1998) and LUCID (2011–2017) studies, several changes have occurred 
in hemodialysis care, including more widespread use of biocompatible and high-flux 
membranes, lowering of hemoglobin targets, the development of activated vitamin D 
analogues and calcimimetics, a focus on “fistula first” for dialysis access, and near universal 
attainment of Kt/Vurea targets. In parallel, numerous changes have occurred in the treatment 
of common comorbidities in patients on dialysis, including the management of hypertension, 
diabetes, and cardiovascular disease. Yet, we found only small differences in any individual 
symptom between CHOICE and LUCID. Because these analyses focused on baseline-
symptom assessments among patients on incident dialysis, it is possible they did not reflect 
the full benefit of hemodialysis over a longer period of time on relieving uremic symptoms. 
However, we found that there was no difference in symptoms among participants in the 
CHOICE study from baseline to 1-year follow-up. This is consistent with a prior study that 
also showed no change in symptoms in a cohort of 97 patients surveyed twice over the 
course of 1 year (18). Taken together, these findings show that minimal progress has been 
made over the past 20 years in relieving symptom burden in ESKD, and that progress in this 
area is unlikely to be achieved by minor adjustments in current practice parameters.
The pathogenesis of uremic symptoms remains poorly characterized (19). Clearly, other 
factors such as anemia, depression, gastroparesis, and medications can contribute to 
symptom burden. Nevertheless, the observation that uremic symptoms improve markedly or 
resolve completely after kidney transplantation has led to the long-standing view that uremic 
symptoms are due, at least in part, to retained uremic toxins (20-24). Based on a given 
toxin’s physical properties (size, protein binding, volume of distribution, etc.) and origin 
(endogenous, diet, microbiome, etc.), one could theoretically design more specific treatment 
approaches, including both dialytic and nondialytic therapies (7). The traditional bench-to-
bedside paradigm has involved demonstrating solute toxicity in vitro or in animal models 
followed by development of targeted assays and clinical validation. This approach, in 
conjunction with traditional analytical techniques, has identified approximately 150 uremic 
solutes over the last >40 years (25), but many are not toxic whereas others have shown 
mixed associations in clinical studies (26). Although the progress in identifying toxins 
responsible for uremic symptoms has been relatively slow, it is possible that emerging high-
throughput approaches in well phenotyped dialysis cohorts may accelerate this process. As 
an example, Kurella Tamura et al. (27) recently used liquid chromatography, mass 
spectrometry–based metabolite profiling to identify 4-hydroxyphenylacetate, 
phenylacetylglutamine, hippurate, and prolyl-hydroxyproline as novel markers of cognitive 
impairment in participants of the Frequent Hemodialysis Network trial.
Our study has several strengths. We examined two multicenter ESKD cohorts, with >1300 
patients in aggregate. CHOICE has longitudinal follow-up with extensive pheno-typing, 
whereas LUCID is more reflective of contemporary practice in the United States. To assess 
symptoms, we used patient responses to similar questions on the Health Experience 
Questionnaire in CHOICE and the KDQOL in LUCID, respectively. Both instruments have 
been validated, and the KDQOL has emerged as the most widely used tool for health-related 
quality of life assessment in the nephrology literature. In fact, the KDQOL is administered 
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annually to patients on dialysis in the United States to meet the requirements of the Center 
for Medicare and Medicaid Services for incorporating assessment of health-related quality 
of life into ESKD care (28).
Several limitations also warrant mention. Although questionnaires permit accrual of large 
sample numbers and comparison across data sets, they may not be ideal for assessment of 
some symptoms. For example, compared to an extensive neurocognitive battery, the 
KDQOL has been shown to have limited sensitivity and specificity for identifying worse 
executive function and memory (29). In addition, we did not consider all potential uremic 
symptoms related to ESKD, e.g., restless legs, or all questions that could be related to a 
given symptom. However, this is also a limitation of the symptom score generated from the 
KDQOL, which includes some but not all questions related to fatigue and lack of energy. To 
address this limitation of existing instruments, rigorous studies are needed to develop 
validated tools for specific uremic symptoms with gold-standard methods that objectively 
assess symptom severity. For example, severity of pruritus can be quantified using 
actigraphy (30,31), and fatigue can be assessed using the Borg rating of perceived exertion 
scale in response to a standardized, 5-minute slow-paced treadmill walk (0.67 m/second; 1.5 
mph) at 0% grade, as was done in the Baltimore Longitudinal Study of Aging (32,33). 
Further, selection bias in those who chose to answer baseline symptom questionnaires, 
survival bias in those who were available to answer the year 1 questionnaire in CHOICE, 
and the vintage of CHOICE may all limit the generalizability of our findings. Finally, 
although symptoms are known manifestations of uremia, they are also known manifestations 
of other clinical conditions such as anemia, hyperphosphatemia, and depression, further 
complicating the exploratory examination of uremic symptoms and longitudinal outcomes.
In conclusion, uremic symptoms are common, persistent, and associated with poor 
outcomes, but their cause remains unknown. In addition, the identification of toxins 
responsible for uremic symptoms remains an important priority, with the goal to develop 
more specific treatment approaches and to improve quality of life, and perhaps long-term 
outcomes, in ESKD.
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Figure 1. ∣. Many individuals in CHOICE and LUCID have multiple uremic symptoms.
The y axis shows the percentage of each study cohort (N=926 in CHOICE and N=428 in 
LUCID) with the corresponding number (#) of uremic symptoms shown on the x axis. 
CHOICE, Choices for Health Outcomes in Caring for ESRD; LUCID, Longitudinal United 
States/Canada Incident Dialysis.
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Table 1.
Baseline characteristics of CHOICE and LUCID participants
Characteristic CHOICE LUCID
Sample size 926 428
Demographics
 Age, yr 58±15 60±15
 Male sex 491 (53%) 258 (60%)
 Black race 257 (28%) 137 (32%)
Clinical characteristics
 Diabetes 498 (54%) 231 (54%)
 ICED score 1.9±0.8 —
 Residual kidney function 749 (81%) 379 (89%)
 BMI, kg/m2 27.1±6.7 28.9±7.7
Dialysis characteristics
 Dialysis modality, hemodialysis 697 (75%) 413 (97%)
 Cause of ESKD, diabetes 423 (46%) 155 (36%)
Predialysis laboratory tests
 BUN, mg/dl 56.9±16.3 —
 Kt/Vurea 1.3±0.4 —
 Albumin, g/dl 3.6±0.4 —
 Creatinine, mg/dl 7.3±2.5 —
 Calcium, mg/dl 9.1±0.7 —
 Phosphate, mg/dl 5.2±1.3 —
 Potassium, mEq/L 4.5±0.6 —
 Glucose, mg/dl 167±86 —
 Cholesterol, mg/dl 190±48 —
Values for categoric variables are given as count (%); values for continuous variables, as mean±SD. CHOICE, Choices for Health Outcomes in 
Caring for ESRD; LUCID, Longitudinal United States/Canada Incident Dialysis; ICED, Index of Coexistent Disease; BMI, body mass index.
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Table 2.







Fatigue 89 89 77
Anorexia 44 43 44
Pruritus 72 74 63
Sleepiness 86 87 68
Nausea/vomiting 36 40 43
Difficulty concentrating 55 60 57
Pain 82 85 79
CHOICE, Choices for Health Outcomes in Caring for ESRD; LUCID, Longitudinal United States/Canada Incident Dialysis.
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